Guillaume Lessene led the study at the Walter and Eliza Hall
Institute scientists have developed a world-first compound that keeps cells alive and healthy when they otherwise would have died.
At a glance
- A world-first ‘cell death blocker’ is able to keep cells alive and functioning in the laboratory.
- The compound is exceptional because it intervenes early, before irreversible cell damage occurs.
- Applications could eventually include preserving organs for transplants and preventing degenerative diseases.
Before it’s too late
The ability to swiftly intervene and prevent cell death – or apoptosis – could be game-changing for medical emergencies and procedures, such as minimising cellular damage after heart attacks, or preserving organs for transplants.
The preclinical findings, published in the journal Nature Chemical Biology, follow 11 years of collaborative research at the Walter and Eliza Hall Institute of Medical Research – a world leader in cell death studies. The study was led by Professor David Huang, Professor Guillaume Lessene and Professor Benjamin Kile, who is now at Monash University.
Professor Lessene, head of the Institute’s New Medicines and Advanced Technologies theme, said the new ‘cell death blocker’ was exceptional for its ability to keep cells alive and healthy in the laboratory.
“Never before have we seen such promising ability to intervene in the earliest stages of apoptosis before irreversible damage occurs,” Profesor Lessene said.
Invaluable for future of medicine
Professor Huang, a laboratory head in the Institute’s Blood Cells and Blood Cancers division, said the ability to stop unwanted cell death could be invaluable for the future of medical care.
“Acute injury can cause cells to die rapidly leading to the loss and weakening of tissues and muscles. In such circumstances, being able to prevent uncontrolled cell death could improve a patient’s recovery, or even their chances of survival,” Professor Huang said.
Apoptosis is a form of tightly regulated cell death essential for health and development. This process is controlled by the ‘BCL-2 family’ of proteins. Within this family, some proteins promote cell survival, while others drive cell death. Proteins called BAK and BAX are involved in a critical step of cell death known as the ‘point of no return’. Cells are committed to die once either BAK or BAX is activated.
Professor Kile, Head of Anatomy and Developmental Biology at the Monash Biomedicine Discovery Institute, said the compound successfully disabled BAK. “In laboratory models we found we could override apoptosis and keep cells functioning,” he said. “We have shown it is possible to halt the biochemical cascade that triggers cell death, right at the point where it begins.”
National Drug Discovery Centre
The proof-of-concept drug was developed through extensive medicinal chemistry following a high-throughput screening campaign of a quarter of a million potential small drug molecules. The laboratories involved have since formed the foundation of the Walter and Eliza Hall Institute’s National Drug Discovery Centre, a world-class facility that has opened for scientists across Australia to pursue their drug discovery journeys.
The Institute’s expertise in cell death research spans more than 30 years, beginning with the landmark discovery in the late 1980s that the protein BCL-2 could enable prolonged cancer cell survival. This critical discovery helped to inform the development of an anti-cancer treatment for patients with leukaemia.
This latest research shines light on ‘the other side of the same coin’; offering hope that one day drugs that successfully intervene to block apoptosis could be used to treat conditions such as cardiovascular diseases and degenerative disorders.
The researchers are now looking to apply the knowledge to developing cell death blockers that are effective and safe in humans. Professor Huang said the next steps would also involve applying the knowledge we have gained to more advanced models of disease.
“There could be applications for keeping cells alive to prevent degenerative diseases,” Professor Huang said.
The research was supported by the Australian Cancer Research Fund, Australian National Health and Medical Research Council, Brownless Trust, DHB Foundation, HEARing CRC, MuriGen Therapeutics, Sylvia and Charles Viertel Foundation and the Victorian Government.